Cargando…

Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel

BACKGROUND: An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS. METHODS: This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Matthew R., Graham, Ciaren, D’Amato, Alfonsina, Gentry-Maharaj, Aleksandra, Ryan, Andy, Kalsi, Jatinderpal K., Whetton, Anthony D., Menon, Usha, Jacobs, Ian, Graham, Robert L. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738042/
https://www.ncbi.nlm.nih.gov/pubmed/31388184
http://dx.doi.org/10.1038/s41416-019-0544-0
_version_ 1783450770320916480
author Russell, Matthew R.
Graham, Ciaren
D’Amato, Alfonsina
Gentry-Maharaj, Aleksandra
Ryan, Andy
Kalsi, Jatinderpal K.
Whetton, Anthony D.
Menon, Usha
Jacobs, Ian
Graham, Robert L. J.
author_facet Russell, Matthew R.
Graham, Ciaren
D’Amato, Alfonsina
Gentry-Maharaj, Aleksandra
Ryan, Andy
Kalsi, Jatinderpal K.
Whetton, Anthony D.
Menon, Usha
Jacobs, Ian
Graham, Robert L. J.
author_sort Russell, Matthew R.
collection PubMed
description BACKGROUND: An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS. METHODS: This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers, (CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z and C-reactive protein); by scoring the specificity associated with dysregulation from the baseline expression for each individual. RESULTS: The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set. Samples were analysed as a simulated annual screening programme, the algorithm diagnosed cases with >30% PPV 1–2 years pre-diagnosis. For Type II cases (~80% were HGS) the algorithm classified 64% at 1 year and 28% at 2 years tDx as severe. CONCLUSIONS: The panel has the potential to diagnose EOC one-two years earlier than current diagnosis. This analysis provides a tangible worked example demonstrating the potential for development as a screening tool and scrutiny of its properties. Limits on interpretation imposed by the number of samples available are discussed.
format Online
Article
Text
id pubmed-6738042
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67380422019-09-12 Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel Russell, Matthew R. Graham, Ciaren D’Amato, Alfonsina Gentry-Maharaj, Aleksandra Ryan, Andy Kalsi, Jatinderpal K. Whetton, Anthony D. Menon, Usha Jacobs, Ian Graham, Robert L. J. Br J Cancer Article BACKGROUND: An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS. METHODS: This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers, (CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z and C-reactive protein); by scoring the specificity associated with dysregulation from the baseline expression for each individual. RESULTS: The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set. Samples were analysed as a simulated annual screening programme, the algorithm diagnosed cases with >30% PPV 1–2 years pre-diagnosis. For Type II cases (~80% were HGS) the algorithm classified 64% at 1 year and 28% at 2 years tDx as severe. CONCLUSIONS: The panel has the potential to diagnose EOC one-two years earlier than current diagnosis. This analysis provides a tangible worked example demonstrating the potential for development as a screening tool and scrutiny of its properties. Limits on interpretation imposed by the number of samples available are discussed. Nature Publishing Group UK 2019-08-07 2019-09-10 /pmc/articles/PMC6738042/ /pubmed/31388184 http://dx.doi.org/10.1038/s41416-019-0544-0 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Russell, Matthew R.
Graham, Ciaren
D’Amato, Alfonsina
Gentry-Maharaj, Aleksandra
Ryan, Andy
Kalsi, Jatinderpal K.
Whetton, Anthony D.
Menon, Usha
Jacobs, Ian
Graham, Robert L. J.
Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
title Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
title_full Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
title_fullStr Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
title_full_unstemmed Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
title_short Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
title_sort diagnosis of epithelial ovarian cancer using a combined protein biomarker panel
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738042/
https://www.ncbi.nlm.nih.gov/pubmed/31388184
http://dx.doi.org/10.1038/s41416-019-0544-0
work_keys_str_mv AT russellmatthewr diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel
AT grahamciaren diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel
AT damatoalfonsina diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel
AT gentrymaharajaleksandra diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel
AT ryanandy diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel
AT kalsijatinderpalk diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel
AT whettonanthonyd diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel
AT menonusha diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel
AT jacobsian diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel
AT grahamrobertlj diagnosisofepithelialovariancancerusingacombinedproteinbiomarkerpanel